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Abstract
Objective—To repor the study of a multigenerational Swiss family with dopa-responsive dystonia
(DRD).
Methods—Clinical investigation was made of available family members, including historical and
chart reviews. Subject examinations were video recorded. Genetic analysis included a genome-wide
linkage study with microsatellite markers (STR), GTP cyclohydrolase I (GCH1) gene sequencing,
and dosage analysis.
Results—We evaluated 32 individuals, of whom 6 were clinically diagnosed with DRD, with
childhood-onset progressive foot dystonia, later generalizing, followed by parkinsonism in the two
older patients. The response to levodopa was very good. Two additional patients had late onset dopa-
responsive parkinsonism. Three other subjects had DRD symptoms on historical grounds. We found
suggestive linkage to the previously reported DYT14 locus, which excluded GCH1. However, further
study with more stringent criteria for disease status attribution showed linkage to a larger region,
which included GCH1. No mutation was found in GCH1 by gene sequencing but dosage methods
identified a novel heterozygous deletion of exons 3 to 6 of GCH1. The mutation was found in seven
subjects. One of the patients with dystonia represented a phenocopy.
Conclusions—This study rules out the previously reported DYT14 locus as a cause of disease, as
a novel multiexonic deletion was identified in GCH1. This work highlights the necessity of an
accurate clinical diagnosis in linkage studies as well as the need for appropriate allele frequencies,
penetrance, and phenocopy estimates. Comprehensive sequencing and dosage analysis of known
genes is recommended prior to genome-wide linkage analysis.
Dopa-responsive dystonia (DRD) is a rare disorder characterized by childhood-onset
fluctuating foot dystonia, which later generalizes and becomes associated with tremor and
parkinsonism.1–3 Response to small doses of levodopa is dramatic. In its classic form, also
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known as Segawa disease, the transmission is autosomal dominant, with variable penetrance.
Most of the cases are due to a mutation in the GTP cyclohydrolase I gene (GCH1; DYT5; MIM:
600225) on chromosome 14q22.1-q22.2, the product of which is an enzyme needed for
tetrahydrobiopterin (BH4) synthesis.4 BH4 is a cofactor of tyrosine hydroxylase (TH), the rate-
limiting enzyme for dopamine synthesis. A recessive form of DRD can be caused by mutations
in the TH gene.5
Although close to 100 mutations have been described in GCH1,6 comprehensive screening
fails to identify the responsible mutation in 40 to 50% of the families.7 Recently, families have
been described with heterozygous exonic deletions in GCH1, which were not detected by
conventional screening techniques.8–11
In this study, we report more comprehensive clinical and genetic investigations of a
multigenerational DRD family, in which a previous study had found linkage to a novel locus
nominated DYT14 on chromosome 14q13, adjacent to the DYT5 locus.12 Expanded data
allowed us to exclude DYT14, and to identify a novel deletion in GCH1 as the disease-causing
mutation in this family.
METHODS
Genealogy and clinical evaluations
Information on the pedigree was collected by means of historical material, family records, and
medical charts review, along with interviews with elderly family members.
The project was approved by the local ethics committee. After signing an informed consent,
subjects underwent a detailed videotaped neurologic evaluation. A clinical diagnosis of definite
DRD was established in patients with childhood onset foot dystonia, and in patients with late
onset dopa-responsive parkinsonism with a history of childhood onset foot dystonia. A clinical
diagnosis of probable DRD was established in obligate carriers with mild symptoms, and in
subjects with suggestive but insufficient history or phenotype. Multiple evaluations were
performed with a maximum follow-up of 7 years. Videotapes were reviewed by at least two
out of five neurologists trained in movement disorders (C.W., M.H., A.S., J.G., F.V.), and a
consensus was reached regarding clinical diagnoses.
In individuals who were confirmed to harbor the mutation, the diagnosis was changed to
genetically proven DRD.
Genetic investigations
Since previous data had pointed to a locus outside GCH1, and direct sequencing of GCH1
exons and flanking intronic sequence showed no mutation,12 our initial approach included a
whole-genome search using single nucleotide polymorphisms (SNP) and follow-up studies
using microsatellite markers.
SNP genotyping
All family members with DNA available were genotyped using the Affymetrix 10K GeneChip
Mapping array with previously described protocols.13 Linkage analysis was performed using
Genespring GT software, with analysis settings as described below for the microsatellite
genotyping.
Microsatellite genotyping
Short tandem repeats (STR) markers over chromosome 14 were chosen using both existing
STR panels (Applied Biosystems, Foster City, CA) and the NCBI database. PCR reactions
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were performed, resulting products were analyzed, and genotype calls were made as previously
described.14 Two-point analysis was performed using a modified version of AUTOSCAN/
MLINK15 under an autosomal dominant model with the disease allele frequency set at 0.001.
Two different penetrance models were used. First, as DRD is twice as penetrant in females
than males within this pedigree and in prior DRD pedigrees,16 sex-specific penetrance classes
of 0.8 for females and 0.4 for males were considered. Second, a more conservative affecteds
only analysis was performed by modeling the penetrance at 0.01. Marker allele frequencies
were set as equally frequent in all analyses. Subsequent analysis systematically dropped
individuals designated as affected in the pedigree to at risk, and recalculated evidence for
linkage. Model-based multipoint linkage analysis was also performed using SIM-WALK217
with the same settings as for two-point analysis.
Candidate gene sequencing
All coding exons of GCH1 were amplified by PCR using primers designed to flanking intronic
sequence (primers sequences available upon request). PCR reactions and sequence analysis
were performed as previously described.18
GCH1 dosage
Duplex semiquantitative PCR was performed, amplifying all six GCH1 exons (primers
sequences available upon request) along with one of three different diploid internal controls,
of 222, 280, and 328 bp. PCR conditions were empirically determined to remain in the log-
linear range with 1 minute denaturation at 94 °C, followed by 25 cycles consisting of 30 seconds
of denaturation at 94 °C, 30 seconds of annealing at 55 °C, and 2 minutes of extension at 72 °
C, with a final period of extension at 72 °C for 5 minutes. We used 20 ng of DNA, with 0.02U
Taq polymerase (CLP, San Diego, CA), 5% Q solution, and 1× Mg-containing buffer (both
from Qiagen) in a 15 μL volume. All forward primers were labeled with fluorescein (6-FAM).
The PCR products were run on an ABI 3730 genetic analyzer (Applied Biosystems), and the
results were analyzed with GeneMap-per v. 4.0 (Applied Biosystems). We calculated the ratio
of exon peak height to control peak heights in affected patient samples, and compared values
to standards obtained from normal, diploid subjects under the same experimental conditions.
Three independent amplifications were performed for each subject/exon, the mean ratio and
SD was used to define heterozygous deletions or duplications.
Deletion mapping
For exact mapping of the deletion, a stepwise procedure was used. First, two markers were
identified that flanked the breakpoints of the deleted region, delineating genomic intervals at
each extremity. The 5′ telomeric and 3′ centromeric intervals were re-iteratively divided into
progressively smaller genomic segments; new primers were designed to amplify new
amplicons at evenly spaced intervals (primers sequence available upon request). Genomic
dosage was subsequently assessed in the log-linear range, as described above. When the region
expected to harbor the genomic breakpoint was <3 kb, long-range PCR was attempted using
appropriate primers and the Expand Long Template PCR System (Roche Diagnostics,
Mannheim, Germany), using the recommended protocol. The PCR product was sequenced as
detailed above. Bioinformatic analysis within and flanking the deleted region was performed
in silico using the Censor software tool.19
Other genetic analyses
Subjects who displayed only parkinsonism were assessed for the most frequent dominantly
inherited missense mutations in SCNA (A53T, E46K, A30P) and LRRK2 (G2019S, R1441C).
20
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Imaging
The proband (VI-1) had brain MRI, employing standard techniques.
RESULTS
Genealogy
The family originates from the region of Bern, in the western part of Switzerland. It is a seven-
generation pedigree with 132 individuals (figure 1), in which dystonia has an autosomal
dominant mode of transmission. After the proband came to our attention in 1995, we were able
to investigate 32 subjects.
Clinical description
Detailed clinical description of the proband is available at appendix E-1 on the Neurology®
Web site at www.neurology.org.
In six patients, a clinical diagnosis of definite DRD was established with childhood onset
dystonia that led to major motor impairment in three subjects (see figure 1 and table). Of these
six patients, three were evaluated as young adults (VI-1, VI-3, VI-4), two with pure dystonia
(VI-1, VI-3) and one with atypical features (VI-4, see below). Three patients were seen in later
life, two with severe parkinsonism and dystonia (IV-4, IV-6) (untreated) and one with mild
dystonia (V-3) (treated). Response to levodopa was very good in the four subjects in whom it
was introduced (two patients refused treatment), with a mean daily intake of 234 mg.
Two patients were diagnosed with probable DRD (IV-1 and V-2). In contrast, two patients
from a more distant branch of the family (IV-9 and IV-10) presented with late-onset (60 and
63 years) asymmetric dopa-responsive parkinsonism.
Three subjects had DRD-suggestive symptoms on historical grounds (IV-3, V-4, III-3). They
were probably affected with the same disease, first because of the pedigree structure (each of
them was the father of an affected individual, with an obligate carrier status), and second
because at least two family members recalled them having symptoms similar to their affected
sons or daughters.
Among the unaffected subjects, eight had bilateral hip dysplasia, of which four had to undergo
surgical hip replacement. Two affected and two unaffected subjects presented with dorsolum-
bar scoliosis, but only in the proband (VI-1) was spine surgery performed.
Genetics
Linkage analysis using both SNP and microsatellite data confirmed the previous chromosome
14q locus, DYT14,12 as harboring the disease gene with a maximum multipoint lod score of
3.6. The shared haplotype spanned approximately 24 cM (D14S283-D14S70), and excluded
GCH1. However, systemic re-analysis of linkage results was performed, specifying “affected”
individuals as “at risk.” Reclassification of person VI-4 alone decreased the maximum
multipoint lod score from 3.6 to 1.8 and the maximum gender-specific two-point lod score
from 2.03 to 0.99 (lod score tables are available at appendix E-1), but expanded the
chromosome 14q disease-associated haplotype to greater than 110 cM (D14S283-D14S292)
which now included GCH1. The most parsimonious haplotype consistent with microsatellite
genotyping and information on chromosomal phase is illustrated on the pedigree (figure 1).
With this new analysis, we re-sequenced GCH1 in affected family members but no mutation
was identified, suggesting that if GCH1 harbored a mutation it would likely be noncoding or
quantitative.
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Recently, mutations have been described in patients with DRD that create null alleles through
genomic deletions of one or more GCH1 exons.8–11 Therefore we decided to screen for a
similar deletion in our family.
Subsequent dosage analysis, higher resolution mapping, and sequencing identified a
heterozygous 54,148 bp deletion of GCH1 in seven subjects, in whom a diagnosis of genetically
proven DRD was established (table and figure 1). The deletion started in intron 2, included
exons 3 to 6, and ended between GCH1 and the neighboring gene, SAMD4A (figure 2). The
Affymetrix 10K SNP chip had no SNPs within the deleted interval, therefore the SNP data
alone would not have identified this region as harboring a deletion.
The GCH1 deletion was not found in subjects on the right-hand branch of the pedigree.
However, individuals IV-7, V-6, IV-4, and IV-9 shared three STR genotypes with the affected
subjects of the left-hand branch of the pedigree (figure 1), which did not encompass GCH1. In
the CEPH database, the reported frequency for the alleles of the first two markers D14S283
and D14S275 was 25 and 30%, but the allele of the third marker D14S70 was not reported,
suggesting that it is rare.
Coding mutations in SNCA and LRRK2 were excluded in Patients IV-9 and IV-10 with
parkinsonism.
Clinical data in light of the genetic results
Two patients who were clinically diagnosed with probable DRD were shown to harbor the
mutation and thus have genetically proven DRD (IV-1 and V-2).
In one of the patients initially diagnosed with clinically definite DRD (VI-4), our genetic
evaluation failed to identify a GCH1 mutation. This patient had a complex clinical presentation:
he not only exhibited dystonia, but he was also mildly mentally retarded, had had epileptic
seizures, and had been treated with antipsychotics for behavioral troubles.
DISCUSSION
Our Swiss family displayed a dominantly inherited DRD phenotype, which affected seven
genetically proven patients spanning three of the seven generations. We found a large genomic
deletion in GCH1 that was sufficient to explain neurologic symptoms in the majority of family
members. Genome-wide SNP linkage analysis failed to identify any other chromosomal region
that segregated as well with the disease.
The phenotype in our seven patients was consistent with that reported in families with dominant
DRD.21 The clinical picture ranged from minor effort-induced dystonic symptoms that were
stable or even improved over 50 years, to patients with severe parkinsonism and dystonia
requiring the use of a wheelchair.16,22,23 Parkinsonism was most pronounced in the elderly
patients, in good agreement with previous reports.21 Gender seemed to have a major influence
on phenotypic severity, since all three severely affected patients were women, and the fourth
woman with milder symptoms had been treated with levodopa for a long time prior to
examination. In contrast, the three male mutation carriers did not have significant functional
impairment and as a result none was treated with levodopa. A penetrance 2.3 times higher in
women than in men has been reported for DRD, and the female-to-male ratio is generally found
to be around four.24 Previous studies have shown that basal GCH1 mRNA25–27 and
protein28 expression levels are lower in nigrostriatal dopaminergic neurons as compared to
neurons producing serotonin and norepinephrine. Moreover, expression was significantly
lower in female than in male mice,26 suggesting that DRD may result from neuron-specific
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nigrostriatal GCH1 haploinsufficiency, which is more pronounced in females due to lower
basal GCH1 gene expression.29
Response to low doses of levodopa was dramatic in all the young patients in whom it was
assessed, without any dyskinesia upon treatment initiation.30 The beneficial effect of levodopa
remained complete after more than 7 years, in agreement with previous reports.21 This suggests
that levodopa treatment may prevent worsening of motor impairment, and underscores the
importance of evaluating clinical improvement with levodopa in every dystonic patient.
Several reports have found a high prevalence of psychiatric manifestations in the form of
depression, anxiety, or obsessive compulsive disorders.23,31 Although our evaluation protocol
did not specifically focus on the detection of such symptoms, we did not find overt psychiatric
disease. Also, our patients did not complain of significant sleep difficulties, as reported in prior
studies.31
We identified a novel mutation in this DRD kindred, a 54.1 kb deletion in GCH1, spanning
exons 3 to 6. The deletion may be explained by the presence of repetitive sequence elements,
non-long terminal repeats retro-transposons, which we found to flank the deleted region. Our
results show the previously described DYT14 locus in this family is erroneous, and call for its
removal from the list of loci linked to DRD.12 Linkage to this region, which we reproduced
in our first round of genetic investigations, probably resulted from misclassification of one
subject as affected (VI-4). Careful reanalysis with more stringent criteria showed the haplotype
segregating with the disease to include GCH1. Patient VI-4 was initially diagnosed with
clinically definite DRD, and he later proved to be a phenocopy. Among the atypical features
he presented, mental retardation may occur in DRD, although it is not a feature of the classic
form of the disease.21 The shared alleles, which initially suggested linkage to the wrong locus,
DYT14, could be relatively common among subjects from this specific region, even though
some are not reported in the CEPH database.
Genetic testing allowed diagnosis to be established in two subjects who were previously only
regarded as probably affected. In one of them, the very mild phenotype precluded a definite
diagnosis, whereas in the other, diagnostic uncertainty came from the association with a second
functionally impairing disease. Further illustrating the difficulty of correctly assigning
affection status in this disease, two patients, without the mutation in GCH1, received a
diagnosis of late onset dopa-responsive parkinsonism for which the cause remains to be
identified.
In keeping with the clinically typical DRD findings in our family, brain MRI was normal in
the index case (C.W., personal communication), and brain pathology confirmed severe
hypomelanization in the substantia nigra without cell loss.12
Only eight DRD families with exon deletions in GCH1 have been described so far.8–11 This
type of mutation probably causes disease phenotype by a mechanism of haploinsufficiency,
with the enzyme produced from the intact gene not reaching sufficient amounts for normal
dopamine metabolism.
This study rules out the previously reported DYT14 locus as a cause of DRD, and instead
implicates the DYT5 locus (GCH1). In light of the previous linkage to the DYT14 locus, this
study illustrates the major impact an individual’s affection status attribution can have in
generating false-positive results. Prior linkage simulations studies, using appropriate model
parameters, may highlight this pitfall. Our study also supports the view that gene dosage
analysis is required to exclude mutations in GCH1 in DRD.
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dopa-responsive dystonia
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GTP cyclohydrolase I
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single nucleotide polymorphisms
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Figure 1. Abbreviated pedigree drawing, showing the clinical and the genetic affection status, with
the STR markers haplotypes
Generations are numbered using Roman numerals I through VII. To protect family members,
individuals are represented as diamonds, and the + numbers at the beginning of each generation
line indicate how many individuals were not included in the pedigree drawing. Shared
haplotype in solid, apparent shared haplotype in dashed lines. Arrow: index case. Diagonal
line: deceased individual.
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Figure 2. Deletion in GCH1
(A) The upper panel shows the wild type gene with GCH1 exons numbered 1 to 6 (in white),
the deleted segment (vertical dashed lines), and the neighboring gene SAMD4A (in gray); the
lower panel shows the mutant gene with the deletion, delineating the fragment (dashed lines)
amplified in (B) in individuals VI-1 and VI-3. (C) Sequence chromatogram showing where the
deletion starts (sample sequence not matching the wild type sequence). Note the CATG
preceding the breakpoint, which may map to either the 5′or the 3′ end of the deletion.
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